Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Los Angeles › NPI 1992887814
Lab

Ashley Clinical Diagnostic Laboratory INC

Ashley Clinical Diagnostic Laboratory INC was paid $4.20M by Medicaid between May 2018 and May 2023, across 8 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 72% of everything it billed.

33Billing provider infoASHLEY CLINICAL DIAGNOSTIC LABORATORY INC
LOS ANGELES, CA 90042
33aNPI1992887814assigned 10/19/2006
28Total paid$4.20M
24GClaims113,028
24DCodes billed8
24AFirst – last monthMay 2018 – May 2023
Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#114 of 561
Median peer was paid$222K
This provider vs. median19×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201812$105.54
20208,507$389K
202126,009$885K
202272,687$2.70M
20235,813$225K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 72% 45,872 16,078 $3.01M
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 12% 26,826 10,774 $516K
G2024 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source 8.4% 18,063 7,006 $351K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 7.6% 22,185 7,998 $319K
86328 <1% 34 33 $1K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 22 18 $756.82
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 12 12 $105.54
86769 <1% 14 14 $97.46

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBANSAL, MADHU (CEO)